ImmuCell Corporation heads into its Q1 2026 earnings today with short sellers having already voted with their feet — the question is whether the 16% rally over the past month has run ahead of the fundamentals.
Short positioning has collapsed. SI fell more than 41% over the past month and is now a negligible 0.19% of the free float. Days to cover are just 0.1. The borrow market is equally relaxed: availability is wide open, with utilization at just 0.14% — far below its 52-week peak of 4.54% — and cost to borrow has eased to roughly 6.1% after spending much of April above 7.5%. The unwind looks deliberate: the bulk of the reduction came in two sharp steps, with shares short dropping from around 34,000 in mid-April to under 17,000 by May 13. Bears have largely exited the building ahead of the print.
That short exodus coincided with a sharp re-rating in the stock. ICCC closed Thursday at $8.26, up 16% over the past month, and YTD gains now reach nearly 36%. The RSI at 58 is modestly elevated but not stretched. The ORTEX short score of 30 is unremarkable. None of the signals point to speculative froth — the rally looks more like a genuine re-rating than a squeeze artifact.
The ownership story adds texture. The top holders are concentrated and closely held: Norman Pessin holds 7.1% and recently transferred 401,819 shares to Sandra Pessin, who now holds a fresh 4.4% stake. The CEO change is also visible in the insider data — Michael Brigham sold 24,052 shares at $6.07 in March, while predecessor Paul Te Boekhorst had bought across three sessions in December at prices in the $4.87–$5.50 range. The buying at depressed prices and the subsequent rally tell a coherent story about insiders marking a floor, even if the March sale at $6.07 — well below today's price — looks conservative in hindsight.
With short interest effectively cleared out and the stock up sharply, today's Q1 print will be asked to justify a stock that has nearly doubled off its late-2024 lows — and to show whether the recovery in ImmuCell's animal health business is translating into numbers that can hold the re-rating in place.
See the live data behind this article on ORTEX.
Open ICCC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
